ライフサイエンスコーパス: oral drug

1 as not progressed into clinical trials as an oral drug.

2 e setting of high cumulative exposure to the oral drug.

3 ed by common sensitizers can be modulated by oral drugs.

4 erties that impede the absorption of various oral drugs.

5 permeability can hinder their development as oral drugs.

6 ferent challenges to medicinal chemistry for oral drugs.

7 dherence, or time to treatment initiation of oral drugs.

8 d predict typical and nontypical profiles of oral drugs.

9 lecular weight) than for Rule-of-5 compliant oral drugs.

10 y show a higher BaN count (#BaN) compared to oral drugs.

11 is generally ideal for once daily dosing of oral drugs.

12 inhibitors limit the use of these agents as oral drugs.

13 on and capacity for first-pass metabolism of oral drugs.

14 was, however, an increase in days' supply of oral drugs (5.96 days; 95% CI, 0.64-11.28 days; P = .001

15 o stabilize drug supersaturation and enhance oral drug absorption has recently garnered considerable

16 fer a means to increase the low and variable oral drug absorption of transporter substrates while dec

17 when optimizing ASD formulations to maximize oral drug absorption.

18 er (hASBT) may serve as a prodrug target for oral drug absorption.

19 ate for long-lasting maintenance as it is an oral drug, active against DLBCL that can be taken for ye

20 profile with the added advantage of being an oral drug administered at home.

21 al to provide alternatives to lifelong daily oral drug administration across the pediatric age spectr

22 Oral drug administration remains the preferred route for

23 , or any condition that could interfere with oral drug administration.

24 , or any condition that could interfere with oral drug administration.

25 77 were achieved within 0.5 to 4 hours after oral drug administration.

26 ide (COS) as a safe, low-cost, and effective oral drug AE.

27 good preclinical properties suitable for an oral drug, albeit a relatively short plasma half-life.

28 testinal loops, common methods for assessing oral drug and nanoparticle absorption, we found that bot

29 ed therapeutic window compared to the parent oral drug, and low cost of goods sold (COGS) at less tha

30 e >/= 1 y, weight >/= 10 kg, ability to take oral drugs, and informed consent.

31 copies per mL (signifying poor adherence to oral drugs, and often associated with drug resistance);

32 mecromone (4-methylumbelliferone [4-MU]), an oral drug approved in Europe for biliary spasm treatment

33 ctions (DDI) was performed on small-molecule oral drugs approved by the FDA from 2020 to 2024 (n = 10

34 Although most oral drugs are administered QD (67%), BID and TID regime

35 ent options for people with migraine in whom oral drugs are ineffective, slow-acting, or intolerable

36 acts only in its unconverted form, and that oral drugs are instantaneously absorbed across the gut w

37 The majority of newly discovered oral drugs are poorly water soluble, and co-administrati

38 of identifying compounds with fully aligned oral drug attributes, "best-in-class" molecules.

39 nial activity of miltefosine (MLF), the only oral drug available for the treatment of visceral and cu

40 Miltefosine is the only oral drug available for treatment of Indian visceral lei

41 Recently, two anticancer oral drugs, AZD5438 and dabrafenib, were identified as p

42 sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - th

43 uated a new 6 month regimen containing three oral drugs; bedaquiline (B), pretomanid (Pa), and linezo

44 ve the bioavailability of a group of soluble oral drugs by drinking COS solution before administratio

45 Analysis of the 1983-2002 oral drugs by therapy area shows that antiinfectives and

46 0 advanced to a Phase 1 clinical trial as an oral drug candidate for SARS-CoV-2.

47 In contrast to repurposed oral drugs, CEE321 does not display high potency in bloo

48 Five distinct oral drug classes are now available for the treatment of

49 Laquinimod is an oral drug currently being evaluated for the treatment of

50 Albendazole, an oral drug currently used to treat parasitic infections,

51 pisode of care; share of patients prescribed oral drugs; days' supply of oral drugs; medication adher

52 ically address the physiological barriers to oral drug delivery and highlight technologies that may b

53 findings indicate that nanoparticle-mediated oral drug delivery can be potentially improved with depa

54 le target for amino acid ester prodrug-based oral drug delivery enhancement strategies.

55 ASBT, and the development of bile acid-based oral drug delivery for ASBT-targeting, including bile ac

56 Therefore, bile acid transporter-mediated oral drug delivery has been regarded as a feasible and p

57 perspective is to describe these barriers to oral drug delivery in relation to some of the work curre

58 h lycopene may be a promising application in oral drug delivery in various indications.

59 Design of innovative strategies for oral drug delivery is particularly promising for intesti

60 anoparticles find intriguing applications in oral drug delivery since they present a large surface ar

61 We report the engineering of a non-invasive oral drug delivery system for long-term, continuous admi

62 Conventional oral drug delivery system has limitation such as degrada

63 The oral drug delivery system not only leveraged the biologi

64 adds to the state of the art, if used as an oral drug delivery system, is the ability to monitor the

65 Oral drug delivery systems have multiple goals, assessin

66 nologies that may be incorporated into these oral drug delivery systems to further enhance drug uptak

67 ancer drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v) pulmonary drug delivery,

68 livery, drug delivery for localized therapy, oral drug delivery systems, and biologic drug delivery s

69 eutic opportunities compared to conventional oral drug delivery systems, especially for those who suf

70 cial guidelines on IVIVC development for non-oral drug delivery systems.

71 at potential as carriers for therapeutics in oral drug delivery systems.

72 Although patients generally prefer oral drug delivery to injections, low permeability of th

73 nsive DNA hydrogel was further developed for oral drug delivery to the hostile acidic environment in

74 ons for the application of OMS materials for oral drug delivery, especially for poorly water-soluble

75 ific oral therapies and advance personalised oral drug delivery.

76 ne of the major liabilities or obstacles for oral drug delivery.

77 errin, and serve as a versatile platform for oral drug delivery.

78 the potential usage of the DNA hydrogel for oral drug delivery.

79 ing polymers with plethora of advantages for oral drug delivery.

80 as not been well investigated especially for oral drug delivery.

81 nsoluble or multimeric proteins required for oral drug delivery.

82 materials, biomaterials, and pharmaceutical oral drug delivery.

83 particle uptake from the small intestine for oral drug delivery.

84 of appetite, the CAFE can be used to monitor oral drug delivery.

85 l domain (PHD) inhibitors are a new class of oral drugs developed to treat anemia in chronic kidney d

86 rointestinal (GI) absorption of drugs and in oral drug development.

87 The effect of RYGB on oral drug disposition is not well understood.

88 emonstrate that the mean property values for oral drugs do not vary substantially with respect to lau

89 ependent increase in the molecular weight of oral drugs during the past 20 years provides compelling

90 east cancer sample, there was an increase in oral drug expenditures ($244; 95% CI, $41-$446; P = .02)

91 ration, no significant changes were found in oral drug expenditures, IV drug expenditures, or total d

92 abolic and chemical stability in vitro, high oral drug exposure (AUC = 23835.0 h.ng/mL) and bioavaila

93 re is a pressing need for an effective, safe oral drug for both stages of the disease, but this will

94 Miltefosine is an FDA approved oral drug for treating cutaneous and visceral leishmania

95 Miltefosine (MIL), the only oral drug for visceral leishmaniasis (VL), is currently

96 nous drugs for at least 10 days, followed by oral drugs for at least 12 weeks.

97 d and stabilized Gemcitabine as a successful oral drug form against Gemcitabine-resistant and other d

98 The pharmacoeconomic principles that drive oral drug formulation are discussed.

99 ystem should help advance the development of oral drug formulations and might also be useful for drug

100 e overview of its application in traditional oral drug formulations.

101 The oral drug FTY720 affects sphingosine-1-phosphate (S1P) s

102 hat is urgently needed now is an inexpensive oral drug in addition to hydroxyurea, the only drug appr

103 y concentrations with free concentrations of oral drugs in human serum.

104 Several oral drugs, including metformin, were predicted to have

105 ondition responds to and can be treated with oral drugs instead of insulin, which is important clinic

106 ed after 6 months of initial combinations of oral drugs is identifiable at initial evaluation by hemo

107 ophilicity, suggesting that this property in oral drugs is important irrespective of the drug's targe

108 to compare the efficacy and safety of three oral drugs, labetalol, nifedipine retard, and methyldopa

109 the calculated physicochemical properties of oral drugs launched prior to 1983 (864 drugs) and betwee

110 l to monitor the fate of ChNPs encapsulating oral drugs, leading to an in-depth understanding of drug

111 -based design with a focus on improvement of oral drug-like properties.

112 known P2Y receptor antagonists, highlighting oral drug-like receptor antagonists, and considers futur

113 groups likely to have greater potential for oral-drug-like properties.

114 ients prescribed oral drugs; days' supply of oral drugs; medication adherence measured by proportion

115 For oral drugs, medicinal chemists aim to design compounds w

116 th PAH treated upfront with a combination of oral drugs.Methods: The study enrolled 181 treatment-nai

117 All three oral drugs-methyldopa, nifedipine, and labetalol-are via

118 rties is an important, unchanging feature of oral drug molecules.

119 Two oral drugs, molnupiravir and paxlovid (nirmatrelvir/rito

120 rational design and bioeffect evaluation of oral drug nanomaterials and sets up the fundamental know

121 In addition, convalescent plasma, the oral drugs nirmatrelvir/ritonavir and molnupiravir, remd

122 Our study demonstrates that the oral drug obeldesivir (ODV), a nucleoside analog prodrug

123 etamol for the fosfomycin group or an active oral drug or parenteral ertapenem for the comparator gro

124 Examination of oral drug parameters approved before and after the origi

125 e in spending will require more than current oral drug parity laws, such as value-based insurance tha

126 Bioavailability of oral drugs, particularly large hydrophilic agents, is of

127 By the mid-1980s, the effective oral drug, praziquantel, replaced tartar emetic a s trea

128 Many solid-dose oral drug products are engineered to release their activ

129 ew Drug Application (ANDA) submission for ER oral drug products included adequate IVIVC data to enabl

130 In all countries, children unable to take oral drugs received prereferral rectal artesunate irresp

131 y designated sedationist nurses, who used an oral drug regimen (according to weight and age from conc

132 ts ATP-synthase, is a key component of a new oral drug regimen that has revolutionized the treatment

133 Oral drug regimens are the pillar of HIV PrEP, but varia

134 While daily oral drug regimens serve as the cornerstone of HIV PrEP,

135 a local DTH reaction and their modulation by oral drugs remain to be investigated.

136 re promising and has potential for improving oral drug retention and controlled absorption to treat l

137 rapeutic effects of pyridostigmine (PYR), an oral drug stimulating the parasympathetic activity throu

138 VIT-2763 is currently being developed as an oral drug targeting ferroportin for the treatment of bet

139 h respect to other routes of administration, oral drugs tend to be lighter and have fewer H-bond dono

140 either chronically (n=60) or after the acute oral drug test (n=36): 65% of the patients taking mexile

141 The oral drug test correctly predicted long-term effect in 9

142 his is the first report describing use of an oral drug that may enhance HIV-specific CD8+ T cell func

143 elopment of GnRH antagonists has resulted in oral drugs that have fewer side-effects than other thera

144 Second-generation oral drugs that retain function against these mutants ar

145 ese findings are observed for all classes of oral drugs, the issue is especially critical for cancer

146 w widely accepted rule of 5 in the design of oral drugs, the physicochemical properties required for

147 pulmonary angioplasty (BPA), and an approved oral drug therapy with the guanylate cyclase stimulator

148 prevalent neglected tropical diseases using oral drug therapy.

149 ellitus patients, a change in treatment from oral drugs to insulin was often associated with a signif

150 Use of oral drugs to provide symptomatic relief of the movement

151 ties and represent an opportunity to develop oral drugs to treat this devastating disease.

152 adequately responding to chemodenervation or oral drug treatment.

153 their global impact, and the availability of oral drug treatments is an essential step in controlling

154 can be treated simultaneously with existing oral drug treatments, facilitating effective and efficie

155 of the most prevalent diseases have existing oral drug treatments.

156 tforms designed to address these barriers to oral drug uptake.

157 ycles more potent than miltefosine, the only oral drug used for the treatment of the neglected tropic

158 decitabine area under the curve (AUC) of the oral drug was less than 90% of that for intravenous deci

159 The oral drug was well tolerated, and no side effects were d

160 The library of marketed oral drugs was then docked into the best-performing mode

161 After infusions, oral drugs were tapered and withdrawn within 60 days.

162 ointestinal tract may aid the development of oral drugs with greater bioavailability.